Antonio Gil-Gómez, Rocío Muñoz-Hernández, Filomeno Martínez, Fernando Jiménez, Manuel Romero-Gómez
{"title":"Hepatic encephalopathy: experimental drugs in development and therapeutic potential.","authors":"Antonio Gil-Gómez, Rocío Muñoz-Hernández, Filomeno Martínez, Fernando Jiménez, Manuel Romero-Gómez","doi":"10.1080/13543784.2024.2434053","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hepatic encephalopathy (HE) presents a complex pathophysiology, creating multiple potential treatment avenues. This review covers current and emerging treatments for HE.</p><p><strong>Areas covered: </strong>Standard therapies, including non-absorbable disaccharides and rifaximin, are widely used but show inconsistent efficacy. Alternatives such as polyethylene glycol and L-ornithine L-aspartate have been effective in certain cases. Advancements in understanding HE reveal a growing need for personalized treatments. Novel approaches targeting immune modulation and neuroinflammation are under investigation, though clinical translation is slow. Nutritional interventions and fecal microbiota transplantation show potential but lack robust evidence. Innovative therapies like gene and cell therapies, as well as extracellular vesicles from mesenchymal stem cells, present promising avenues for liver disease treatment, potentially benefiting HE.</p><p><strong>Expert opinion: </strong>A key challenge in HE research is the design of randomized clinical trials, which often suffer from small sample sizes, heterogeneity in patient population, and inconsistent blinding. Additionally, the multifactorial nature of HE, together with a high spontaneous response rate, complicates efforts to isolate treatment effects. Despite current limitations, ongoing research and technological advances hold promise for more effective and individualized HE treatments in the future.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1219-1230"},"PeriodicalIF":4.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2024.2434053","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Hepatic encephalopathy (HE) presents a complex pathophysiology, creating multiple potential treatment avenues. This review covers current and emerging treatments for HE.
Areas covered: Standard therapies, including non-absorbable disaccharides and rifaximin, are widely used but show inconsistent efficacy. Alternatives such as polyethylene glycol and L-ornithine L-aspartate have been effective in certain cases. Advancements in understanding HE reveal a growing need for personalized treatments. Novel approaches targeting immune modulation and neuroinflammation are under investigation, though clinical translation is slow. Nutritional interventions and fecal microbiota transplantation show potential but lack robust evidence. Innovative therapies like gene and cell therapies, as well as extracellular vesicles from mesenchymal stem cells, present promising avenues for liver disease treatment, potentially benefiting HE.
Expert opinion: A key challenge in HE research is the design of randomized clinical trials, which often suffer from small sample sizes, heterogeneity in patient population, and inconsistent blinding. Additionally, the multifactorial nature of HE, together with a high spontaneous response rate, complicates efforts to isolate treatment effects. Despite current limitations, ongoing research and technological advances hold promise for more effective and individualized HE treatments in the future.
简介:肝性脑病(HE)的病理生理学十分复杂,具有多种潜在的治疗途径。本综述涵盖肝性脑病的现有治疗方法和新兴治疗方法:包括非吸收二糖和利福昔明在内的标准疗法被广泛使用,但疗效并不一致。聚乙二醇和 L-鸟氨酸-L-天门冬氨酸等替代品在某些病例中有效。随着对高血压认识的不断深入,对个性化治疗的需求日益增长。针对免疫调节和神经炎症的新方法正在研究中,但临床转化缓慢。营养干预和粪便微生物群移植显示出潜力,但缺乏有力的证据。基因和细胞疗法等创新疗法以及间充质干细胞的细胞外囊泡为肝病治疗提供了前景广阔的途径,有可能使肝病患者受益:肝病研究面临的一个主要挑战是随机临床试验的设计,这些试验往往存在样本量小、患者人群异质性和盲法不一致等问题。此外,高血压的多因素性质以及较高的自发反应率也使分离治疗效果的工作变得更加复杂。尽管目前存在种种限制,但正在进行的研究和技术进步为未来更有效、更个性化的 HE 治疗带来了希望。
期刊介绍:
Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.
The Editors welcome:
Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies
Drug Evaluations reviewing the clinical and pharmacological data on a particular drug
Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.